Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$72.56 USD
-0.95 (-1.29%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $72.58 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Earnings News For GILD
-
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
-
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
-
Gilead: Q1 Earnings Snapshot
-
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
-
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
-
Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?
-
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
-
Gilead: Q4 Earnings Snapshot
-
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
-
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
-
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
-
Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales
-
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
-
Gilead: Q3 Earnings Snapshot
-
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
-
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
-
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
-
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
-
Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?
-
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
-
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
-
Gilead: Q1 Earnings Snapshot
-
Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?
-
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
-
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology